---
title: "Kura Oncology, Inc. (KURA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/KURA.US.md"
symbol: "KURA.US"
name: "Kura Oncology, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T11:26:50.714Z"
locales:
  - [en](https://longbridge.com/en/quote/KURA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/KURA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/KURA.US.md)
---

# Kura Oncology, Inc. (KURA.US)

## Company Overview

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [kuraoncology.com](https://kuraoncology.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: D (0.76)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 226 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 5.37% |  |
| Net Profit YoY | -61.95% |  |
| P/B Ratio | 7.37 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 795418310.40 |  |
| Revenue | 71639000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -124.74% | E |
| Profit Margin | -411.19% | E |
| Gross Margin | -258.75% | E |
| Revenue YoY | 5.37% | C |
| Net Profit YoY | -61.95% | D |
| Total Assets YoY | -12.26% | E |
| Net Assets YoY | -70.39% | E |
| Cash Flow Margin | 26.47% | D |
| OCF YoY | 5.37% | C |
| Turnover | 0.10 | E |
| Gearing Ratio | 83.47% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Kura Oncology, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "5.37%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-61.95%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "7.37",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "795418310.40",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "71639000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-124.74%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-411.19%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-258.75%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "5.37%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-61.95%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-12.26%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-70.39%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "26.47%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "5.37%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.10",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "83.47%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.70 | 286/386 | - | - | - |
| PB | 7.37 | 375/386 | 4.24 | 2.97 | 1.57 |
| PS (TTM) | 11.10 | 172/386 | 10.81 | 8.55 | 7.41 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-13T04:00:00.000Z

Total Analysts: **15**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 12 | 80% |
| Overweight | 2 | 13% |
| Hold | 1 | 7% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 8.96 |
| Highest Target | 76.00 |
| Lowest Target | 15.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/KURA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/KURA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/KURA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/KURA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**